Literature DB >> 10438818

Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Y Liu1, J J Chen, Q Gao, S Dalal, Y Hong, C P Mansur, V Band, E J Androphy.   

Abstract

The E6 proteins from cervical cancer-associated human papillomavirus (HPV) types such as HPV type 16 (HPV-16) induce proteolysis of the p53 tumor suppressor protein through interaction with E6-AP. We have previously shown that human mammary epithelial cells (MECs) immortalized by HPV-16 E6 display low levels of p53. HPV-16 E6 as well as other cancer-related papillomavirus E6 proteins also binds the cellular protein E6BP (ERC-55). To explore the potential functional significance of these interactions, we created and analyzed a series of E6 mutants for their ability to interact with E6-AP, p53, and E6BP in vitro. While there was a similar pattern of binding among these E6 targets, a subset of mutants differentiated E6-AP binding, p53 binding, and p53 degradation activities. These results demonstrated that E6 binding to E6-AP is not sufficient for binding to p53 and that E6 binding to p53 is not sufficient for inducing p53 degradation. The in vivo activity of these HPV-16 E6 mutants was tested in MECs. In agreement with the in vitro results, most of these p53 degradation-defective E6 mutants were unable to reduce the p53 level in early-passage MECs. Interestingly, several mutants that showed severely reduced ability for interacting with E6-AP, p53, and E6BP in vitro efficiently immortalized MECs. These immortalized cells exhibited low p53 levels at late passage. Furthermore, mutants defective for p53 degradation but able to immortalize MECs were also identified, and the immortal cells retained normal levels of p53 protein. These results imply that multiple functions of HPV-16 E6 contribute to MEC immortalization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438818      PMCID: PMC104255     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.

Authors:  Y Cao; Q Gao; D E Wazer; V Band
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

2.  Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation.

Authors:  L Sherman; A Jackman; H Itzhaki; M C Stöppler; D Koval; R Schlegel
Journal:  Virology       Date:  1997-10-27       Impact factor: 3.616

3.  A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential.

Authors:  M Elbel; S Carl; S Spaderna; T Iftner
Journal:  Virology       Date:  1997-12-08       Impact factor: 3.616

4.  Transactivation of prothymosin alpha and c-myc promoters by human papillomavirus type 16 E6 protein.

Authors:  T Kinoshita; H Shirasawa; Y Shino; H Moriya; L Desbarats; M Eilers; B Simizu
Journal:  Virology       Date:  1997-05-26       Impact factor: 3.616

5.  Identification of an alpha helical motif sufficient for association with papillomavirus E6.

Authors:  J J Chen; Y Hong; E Rustamzadeh; J D Baleja; E J Androphy
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 6.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

7.  The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP.

Authors:  R C Elston; S Napthine; J Doorbar
Journal:  J Gen Virol       Date:  1998-02       Impact factor: 3.891

8.  The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.

Authors:  A L Talis; J M Huibregtse; P M Howley
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

9.  Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells.

Authors:  P R Daniels; C M Sanders; N J Maitland
Journal:  J Gen Virol       Date:  1998-03       Impact factor: 3.891

10.  Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).

Authors:  L S Gollahon; J W Shay
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

View more
  93 in total

1.  Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.

Authors:  M Nees; J M Geoghegan; T Hyman; S Frank; L Miller; C D Woodworth
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

3.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Authors:  Rozita Bagheri-Yarmand; Anna Biernacka; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 5.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

6.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

7.  Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31.

Authors:  Choongho Lee; Laimonis A Laimins
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc.

Authors:  L Gewin; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents.

Authors:  Zhi-Guo Liu; Li-Na Zhao; Ying-Wang Liu; Ting-Ting Li; Dai-Ming Fan; Jason J Chen
Journal:  J Mol Biol       Date:  2007-09-18       Impact factor: 5.469

10.  Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells.

Authors:  Xiangshan Zhao; Lin Lu; Nidhi Pokhriyal; Hui Ma; Lei Duan; Simon Lin; Nadereh Jafari; Hamid Band; Vimla Band
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.